AMENDMENTS TO THE SPECIFICATION

Please amend Table 3 appearing on page 44 as follows:

Table 1: CDR3 sequences of BV-BJ expansions in CM⁺ mice.

| - | BV | BJ | CDR3 | | Mice | Aminoa | | |
|---|-----|-----|--------|--------|-------------|--------|-------------------------|------|
| | | | Length | | _ | BV | | BJ |
| | | | (aa) | | | | <- CDR3 ^A -> | |
| - | 8.1 | 2.2 | 9/10 | CM+ | #1 | CAS | SGGDXXGQL | YFG |
| | | | | | | | SGGDXXGQL ¹ | |
| | | | | | #2 | CAS | SVGGVNTGQL | YFG |
| | | | | | π2 | CAB | SVGGVNTGQL ² | 110 |
| | | | | | | | 2.00042 | |
| | | | | | #3 | CAS | SVGQENTGQL | YFG |
| | | | | | | | SVGQENTGQL ³ | |
| | 8.1 | 1.5 | 9 | CM+ | #1 | CAS | SEXXDNQAP | LFG |
| | | | | | | | <u>SEXXDNQAP⁴</u> | |
| | | | | | #2 | CAS | SDGQEDQAP | LFG |
| | | | | | 112 | Cris | SDGQEDQAP ⁵ | 21 0 |
| | | | | | | | | |
| | | | | | #3 | CAS | SPGQDNQAP | LFG |
| | | | | | | | SPGQDNQAP ⁶ | |
| | 2 | 1.3 | 9 | CM+ | #1 | CTC | SETGSGNTL | YFG |
| | 2 | 1.5 | | OIVI · | <i>,,</i> , | | SETGSGNTL ⁷ | |
| | | | | | | | | |
| | | | | | #7 | CTC | SVTDSGNTL | YFG |
| | | | | | | | SVTDSGNTL ⁸ | |
| | | | | | #9 | CTC | SETGSGNTL | YFG |
| | | | | | 11) | | SETGSGNTL ⁹ | |
| | | | | | | | | |
| | | | | CM- | #1 | CTC | SXTGSGNTL | YFG |
| | | | | | | | SXTGSGNTL ¹⁰ | |
| | | | | | | | | |

BV-BJ PCR products were directly sequenced for indicated PBL samples using both a BV- and a BJ-specific primers.

AX stands for a position that could not be determined. Following Kabat et al (31), the CDR3 region was taken as

SEQ ID NO: 3 6 SEQ ID NO: 8 ² SEQ ID NO: 4 SEQ ID NO: 9 ³ SEQ ID NO: 5 SEQ ID NO: 10 SEQ ID NO: 11 SEQ ID NO: 6 ¹⁰ SEQ ID NO: 12 ⁵ SEQ ID NO: 7

encompassing amino-acids 95 to 106.

Please amend Table 5 appearing on page 61 as follows:

Table 5: CDR3 direct sequencing of identified PBL expansions in infected mice.

| TCRBJ | CDR3 | Mice | <- CDR3 ¹ Sequences -> | | | | |
|-------|------|------|-----------------------------------|---|---------------------------|-----------------------------|-------|
| | (aa) | | TCRBV2 -> | | | <- | TCRBJ |
| 1.3 | 9 | #1 | CTC | S | XTG | SGNTL SGNTL ² | YFG |
| | | #2 | CTC | S | SAK | SGNTL SGNTL ² | YFG |
| | | #3 | CTC | S | SGT | SGNTL SGNTL ² | YFG |
| 1.1 | 9 | #1 | CTC | S | GTGA GTGA ³ | NTEV NTEV ⁴ | FFG |
| | | #2 | CTC | S | GTGA GTGA ³ | NTEV NTEV ⁴ | FFG |
| | | #3 | CTC | S | XTGA XTGA ⁵ | NTEV NTEV ⁴ | FFG |
| | | #4 | CTC | S | GTGA GTGA ³ | NTEV NTEV ⁴ | FFG |

BV2-BJ PCR products were directly sequenced using both BV- and BJ-specific primers.

Page 111, after the last line, beginning on a new page, please insert the attached Abstract as new page 112.

Page 112 (Abstract), after the last line, beginning on a new page, please insert the attached Sequence Listing.

¹ X stands for a position that could not be determined due to ambiguous reading of the nucleotide sequence. Following (<u>Kabat et al</u>, Sequences of proteins of immunological interest 1991, Bethesda, MD) the CDR3 region was taken as encompassing amino-acids 95 to 106.

² SEQ ID NO: 13

⁴ SEQ ID NO: 15

³ SEQ ID NO: 14

⁵ SEQ ID NO: 16